Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M, ending its run as a pioneer in gene editing.
Despite being an early player in the gene editing field and developing numerous clinical programs, Sangamo Therapeutics will be selling off …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - SANGAMO THERAPEUT
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
At BIO, a glimpse behind Lilly and Chai’s partnership
Gene-editing startup launches with $230 million and a Chinese licensing deal
Another big deal, another sign biotech M&A is back
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230…
RIP Sangamo, onshoring with drug manufacturing, and more biotech news from The Readout
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering…
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now…
The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling…
